Rhumbline Advisers Purchases Shares of 34,940 Tyme Technologies Inc (TYME)
Rhumbline Advisers purchased a new position in shares of Tyme Technologies Inc (NASDAQ:TYME) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 34,940 shares of the company’s stock, valued at approximately $110,000.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Family Management Corp raised its position in shares of Tyme Technologies by 27.3% during the 1st quarter. Family Management Corp now owns 140,000 shares of the company’s stock worth $312,000 after purchasing an additional 30,000 shares during the last quarter. Perkins Capital Management Inc. raised its position in shares of Tyme Technologies by 330.0% during the 2nd quarter. Perkins Capital Management Inc. now owns 101,050 shares of the company’s stock worth $319,000 after purchasing an additional 77,550 shares during the last quarter. Millennium Management LLC raised its position in shares of Tyme Technologies by 551.5% during the 1st quarter. Millennium Management LLC now owns 1,551,315 shares of the company’s stock worth $3,459,000 after purchasing an additional 1,313,190 shares during the last quarter. Finally, Farallon Capital Management LLC acquired a new position in shares of Tyme Technologies during the 1st quarter worth about $3,190,000. Hedge funds and other institutional investors own 11.13% of the company’s stock.
A number of research firms have commented on TYME. Canaccord Genuity reiterated a “buy” rating on shares of Tyme Technologies in a report on Friday, June 15th. BidaskClub downgraded shares of Tyme Technologies from a “sell” rating to a “strong sell” rating in a report on Friday, August 10th. Finally, Zacks Investment Research upgraded shares of Tyme Technologies from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a report on Friday, August 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. Tyme Technologies currently has a consensus rating of “Buy” and an average price target of $7.31.
About Tyme Technologies
Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.
See Also: How to Invest in Growth Stocks
Want to see what other hedge funds are holding TYME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tyme Technologies Inc (NASDAQ:TYME).
Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.